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Therapeutic targets in extracellular protein deposition diseases
Abstract
Many litres of fluids are found outside cells in the human body. These fluids are rich in dissolved proteins
that each have a characteristic three dimensional shape, necessary for normal function, which has been
attained by the correct folding of their polypeptide chain(s). The structure of these extracellular proteins
can be damaged by a variety of environmental stresses (e. g. heat and oxidation) leading to their partial
unfolding and aggregation. This in turn can produce toxic soluble aggregates and/or large insoluble
protein deposits, either of which can disrupt normal body function (e. g. in Alzheimer's disease and the
systemic amyloidoses). A small family of abundant human blood proteins with the ability to inhibit the
aggregation and deposition of stressed (partially unfolded) proteins has been discovered. These
extracellular chaperones (ECs) form stable, soluble complexes with stressed proteins. It has been
proposed that once bound to stressed proteins, ECs guide them to specific cell surface receptors that
direct the "cargo" into lysosomes for degradation. Thus ECs and their receptors may be critical parts of a
quality control system to protect the body against the deleterious effects of inappropriately aggregating
extracellular proteins. This review focuses on the role of extracellular protein aggregation and deposition
in disease, what little is known about mechanisms that act to control these processes, and, lastly,
potential new targets for drug development. Newly identified potential drug targets include direct
inhibition of protein aggregation, and manipulation of the expression levels of ECs and their receptors.
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ABSTRACT
Many litres of fluids are found outside cells in the human body. These fluids are rich in
dissolved proteins that each have a characteristic three dimensional shape, necessary for
normal function, which has been attained by the correct folding of their polypeptide
chain(s). The structure of these extracellular proteins can be damaged by a variety of
environmental stresses (e.g. heat and oxidation) leading to their partial unfolding and
aggregation. This in turn can produce toxic soluble aggregates and/or large insoluble
protein deposits, either of which can disrupt normal body function (e.g. in Alzheimer's
disease and the systemic amyloidoses). A small family of abundant human blood proteins
with the ability to inhibit the aggregation and deposition of stressed (partially unfolded)
proteins has been discovered. These extracellular chaperones (ECs) form stable, soluble
complexes with stressed proteins. It has been proposed that once bound to stressed
proteins, ECs guide them to specific cell surface receptors that direct the "cargo" into
lysosomes for degradation. Thus ECs and their receptors may be critical parts of a quality
control system to protect the body against the deleterious effects of inappropriately
aggregating extracellular proteins. This review focuses on the role of extracellular protein
aggregation and deposition in disease, what little is known about mechanisms that act to
control these processes, and, lastly, potential new targets for drug development. Newly
identified potential drug targets include direct inhibition of protein aggregation, and
manipulation of the expression levels of ECs and their receptors.

Keywords: Extracellular protein unfolding; protein aggregation; protein deposition
diseases; extracellular chaperones; receptor-mediated endocytosis; therapeutic targets.

INTRODUCTION
Environmental stresses can damage proteins and result in their partial unfolding, loss of
function, and aggregation. In the case of extracellular proteins, these stresses can include
heat, oxidation and mechanical sheer stress (e.g. encountered during the pumping of
blood around the body). When a protein is exposed to physical or chemical stresses, the
resulting partial unfolding typically exposes hydrophobic regions, normally buried in the
folded interior of the protein, to the surrounding aqueous solvent. This is energetically
unfavourable and what normally ensues is that regions of solvent-exposed hydrophobicity
on neighbouring protein molecules bind to one another, leading to the formation of
protein aggregates [1]. These aggregates can be toxic to cells or can increase in size to the
point where they form large insoluble protein deposits, either of which can disrupt normal
body function. Many different proteins undergo these same processes and there are a
large number of serious human diseases for which the pathology arises from
inappropriate protein aggregation [2].

Owing to the grave dangers associated with protein unfolding and aggregation, very
elaborate mechanisms have evolved to "quality control" the folding state of proteins. The
mechanisms that operate inside cells have been the subject of intense study for decades
and are relatively well characterised [3]. In stark contrast, until recently, almost no
attention had been paid to the question of how the folding state of secreted extracellular
proteins is monitored or controlled. This is surprising given that inappropriate
aggregation of extracellular proteins underpins the pathology of some of the most
prevalent and pernicious of human diseases (e.g. Alzheimer's disease and type II

diabetes). A significant advance in this field has been provided by the discovery of a
small family of abundant human blood proteins with the ability to inhibit the aggregation
and deposition of stressed (partially unfolded) proteins. These extracellular chaperones
(ECs), which include clusterin, haptoglobin and 2-macroglobulin, form stable, soluble
complexes with stressed proteins [4-6]. It has been proposed that once bound to stressed
proteins, ECs guide them to specific cell surface receptors that direct the "cargo" into
lysosomes for degradation. Thus ECs and their receptors may be critical parts of a quality
control system to protect the body against the deleterious effects of inappropriately
aggregating extracellular proteins [6, 7]. Identifying the elements and mechanisms of this
system will open up new avenues for the development of disease therapies.

PROTEIN UNFOLDING
The vital functions that are carried out by proteins are inherently linked to their correct
folding into unique three-dimensional shapes, referred to as the “native conformation”.
As a consequence of the importance of adopting the native conformation, cells have
extensive quality control mechanisms to monitor the progression of nascent polypeptides
to mature proteins [8]. However, nascent polypeptides may irreparably misfold if RNA
modification, translational amino acid misincorporation, or genetic mutations alter the
primary sequence of the polypeptide. Furthermore, native proteins may partially unfold
when exposed to physiologically relevant stresses resulting in misfolded conformations.
Given that protein stability is collectively determined by all of the interactions
contributing to the native conformation, the stability of different proteins is highly
variable and may change over the lifetime of individual molecules if they become

modified. For example, damage of amino acids by reactive oxygen species (ROS) may
lead to the formation of carbonyl derivatives which distort secondary and tertiary protein
structure and result in partial protein unfolding, increased exposed hydrophobicity,
aggregation and susceptibility to proteolysis [9]. While many antioxidant defenses exist
within cells, aging and diseases such as atherosclerosis, arthritis, muscular dystrophy,
cataract, pulmonary dysfunction, certain neurological disorders and some cancers are
believed to be the result of free radical damage impairing cellular functions [10].
Additionally, heat stress (such as that observed in muscles during exercise) markedly
increases the production of intracellular and extracellular ROS [11]. Aside from
participating in reactions that produce ROS, heavy metals may disrupt protein structure
by breaking internal salt bridges and disulfide bonds. Salt bridges are susceptible to
interference by many compounds including acids and bases due to their ability to
exchange ionic partners. Mechanical stress may also sufficiently disrupt amino acid
interactions to induce protein unfolding [12].

Protein thermostability is only partly understood despite its obvious importance to all
living organisms. Regardless of their relative stability all proteins may be induced to
unfold providing that the kinetic energy (e.g. heat) supplied to the system is sufficient.
The events of protein unfolding are consistent regardless of temperature, however, the
rate at which unfolding can occur is highly dependent on the amount of heat supplied
[13]. The results of in vitro refolding studies have identified that, after the native
conformation is lost, a protein may transition between many possible non-native
intermediate states. However, energy restraints and the loss of conformational entropy

favour the formation of certain intermediates [14]. These intermediate states are often
partially folded, but have regions of unstructured polypeptide backbone and exposed
hydrophobicity [15]. The packaging together of these exposed hydrophobic regions on
non-native proteins and the consequent formation of oligomeric aggregates is
thermodynamically favourable. Protein aggregation is also promoted by the crowded
nature of the intracellular environment, which influences the kinetics and equilibria of
isomerization and protein association reactions [16]. The aggregates formed may be
amorphous, or have an ordered arrangement such as in amyloid fibrils, and eventually
reach sizes that exceed their solubility limit [17]. Under certain conditions, non-native
proteins may be rescued and refolded back into their native conformation by chaperones
(Figure 1).

Figure 1. A schematic representation of the protein unfolding and aggregation pathways. When exposed to
physical or chemical stresses that destabilize protein structure, a protein may traverse the protein unfolding
pathway. This process begins when the protein loses its native three-dimensional structure and adopts a
partially unfolded intermediate conformation. Further destabilization of the protein may lead to complete
unfolding. However, often before a protein can fully unfold, interactions between adjacent partially
unfolded proteins may occur, leading to the formation of either ordered fibrils (e.g. amyloid) or disordered
(amorphous) aggregates. To prevent this, chaperones bind partially unfolded ‘substrate’ proteins and in
some cases can facilitate their refolding to a native conformation.

PROTEIN DEPOSITION DISEASES (PDDs)
Controlled unfolding is important in many biological processes including protein
translocation, degradation by proteases and regulation of enzyme activity.
Additionally, it has been proposed that proteins are dynamic and may constantly
transition between less ordered forms and the native conformation [18]. However,
uncontrolled unfolding or misfolding and the consequent accumulation of protein
aggregates are implicated in the pathology of many diseases collectively known as
Protein Deposition Diseases (PDD) (Table 1). PDDs are typically late-onset [19],
suggesting that the underlying cause of the disease may be disruption or overwhelming
of protein folding quality control mechanisms that were once able to maintain existing
proteins in their native conformation. Although the reasons for the progressive
impairment of fundamental physiological processes in aging is not fully understood, it
is likely that the combination of declining protein folding quality control and exposure
to thermal, ionic, heavy metal or oxidative stress may be responsible for late-onset
PDDs.

Table 1 Examples of Protein Deposition Diseases (PDDs) and the proteins implicated
in their pathology [20-25].

Disease

Protein

Type of Aggregate

Location

Alzheimer’s Disease

Amyloid-

Amyloid

Extracellular

Parkinson’s Disease

-Synuclein

Fibrillar non-amyloid

Intracellular

(Lewy Bodies)
Type II Diabetes

Human islet amyloid polypeptide

Amyloid

Intracellular and
Extracellular

Amylotrophic Lateral Sclerosis

Superoxide dismutase 1

Fibrillar non-amyloid

Intracellular

Haemodialysis-related

β2-Microglobulin

Amyloid

Extracellular

Reactive Amyloidosis

Amyloid-

Amyloid

Extracellular

Huntington’s Disease

Huntingtin

Fibrillar non-amyloid

Intracellular

Creutzfeldt-Jakob Disease

Prion protein

Amyloid

Extracellular

Primary Systemic Amyloidosis

Immunoglobulin light chain

Amyloid

Extracellular

Secondary

Serum amyloid-

Amyloid

Extracellular

Lysozyme

Amyloid

Extracellular

Kerato-epithelin

Amorphous

Extracellular

Immunoglobulin G

Amorphous

Extracellular

62 different proteins

Amorphous (Drusen)

Extracellular

Tamm-Horsfall protein

Amorphous

Extracellular

Amyloid

Extracellular

Amyloidosis

Systemic

Amyloidosis
Hereditary

non-neuropathic

systemic amyloidosis
Corneal dystrophy
Nonamyloidotic

monoclonal

IgG deposition disease
Age-related

macular

degeneration
Renal Disease

Osteopotin
Hereditary Renal Amyloidosis

Fibrinogen

Types of Protein Deposits
All PDDs involve protein misfolding leading to the deposition in tissues of insoluble
protein aggregates, however, the type of aggregate formed varies between the individual
diseases. In many PDDs including Alzheimer’s disease, type II diabetes, systemic
amyloidosis and transmissible spongiform encephalopathy, the deposition of insoluble
aggregates occurs as fibrillar amyloid. The structure and mechanisms underlying the
generation of amyloid are discussed elsewhere [26]. In other PDDs the nature of the
protein deposits is fibrillar, but not amyloid. Non-amyloid fibrillar structures include
Lewy bodies, which are found in Parkinson’s disease, Alzheimer's disease, some other
forms of dementia and occasionally Shy-Drager’s syndrome. Lewy bodies generally
consist of a dense core of filaments and granular material radially surrounded by
additional filamentous structures. However, randomly arranged Lewy body filaments
have been identified in the cerebral cortex of dementia patients [27]. In Pick’s disease,
non-amyloid fibrillar deposits known as Pick bodies accumulate in specific regions of the
central nervous system and contribute towards neuronal damage [28]. Pick bodies consist
of randomly oriented straight filaments and periodical, paired, twisted filaments of
abnormal tau protein [29].

Amorphous, non-filamentous extracellular aggregates formed by IgG light chain and/or
IgG heavy chain are characteristic of nonamyloidotic monoclonal IgG deposition disease
(NAMIDD) [30, 31]. The clinical manifestations of NAMIDD are similar to those of
amyloid-forming IgG deposition disease and include glomerulonephritis as result of an
organ-compromising accumulation of IgG in the kidneys. Pathologic nonamyloid

deposits have also been identified in certain corneal dystrophies. In granular Groenouw
type I corneal dystrophy, the progressive accumulation of non-amyloid deposits
contributes to corneal opacity and the loss of vision [32]. In Avellino corneal dystrophy
both amyloid and non-amyloid material are found co-localized in the cornea [32]. Drusen
are amorphous extracellular deposits that accumulate in patients with age-related macular
degeneration. In healthy eyes drusen are not found in the macula, however they may exist
in the retinal periphery and their size and number are considered a risk factor for
developing age-related macular degeneration later in life [33]. Many different proteins
are found in drusen with crystallins, lactoglobulin, clusterin, complement component 9,
serum albumin, haemoglobin and vitronectin being some of the most abundant and
common [34].

Oxidized IgG aggregates are found in many acute and chronic inflammatory states
including rheumatoid arthritis [35]. These diseases may be considered a special class of
PDDs since oxidized IgG may persist in extracellular fluids as soluble aggregates. IgG
aggregates have immune complex-like properties and stimulate neutrophils to release
ROS thereby inducing the aggregation of previously unaggregated IgG [36]. This selfperpetuating cycle of neutrophil activation, oxidized IgG aggregation and the generation
of damaging ROS is likely to be very important in the pathology of rheumatoid diseases.

Cytotoxicity
While the cytotoxicity of protein aggregates is the focus of many studies, it is unknown
whether the deposition in tissues of protein aggregates is, in fact, the critical event in

pathogenesis. Temporal studies of transgenic animals that express abnormal aggregating
human proteins have not been very successful at identifying the precise pathogenic
species [37]. In diseases such as non-neurological systemic amyloidoses, it appears likely
that the large quantity of protein aggregates deposited in tissues cause the clinical
symptoms of the disease [20, 21, 23-25]. However, at least in the case of some amyloid
diseases there is increasing evidence to suggest that the toxic species may occur early in
the aggregation prior to the formation of mature fibrils. One study of amyloid formation
has reported that amyloid-beta peptide (Aβ), which is important in Alzheimer’s disease
pathogenesis, was cytotoxic once amyloidogenic fibrils were formed, but not while it was
present as an early-stage amorphous aggregate [38]. Conversely, a study of transgenic
mice expressing different mutant forms of Aβ precursor protein showed that behavioural
and cognitive defects in the mice preceded amyloid plaque formation [39]. Similarly,
evidence of tissue damage before amyloid fibrils were formed was documented in a study
of transgenic mice expressing human islet amyloid polypeptide, which is relevant in type
II diabetes [40]. Another recent report provides evidence that several amyloid forming
proteins are cytotoxic during the early stages of aggregation, but that the mature
aggregates themselves are not cytotoxic [41]. If end-point aggregates are not cytotoxic
then it is possible that in some cases their formation may be cytoprotective. In particular
the intracellular localization of unfolded proteins may increase the efficiency of their
autophagic capture and subsequent proteolytic degradation.

Perhaps the most popular theory regarding the cytotoxicity of protein aggregates involves
the production of ROS. It has been suggested that cumulative oxidative damage may be

responsible for many PDDs including Alzheimer’s disease [42] and age-related macular
degeneration [43]. While oxidative stress is a known factor contributing to the unfolding
and aggregation of proteins, there is increasing evidence that the accumulation of protein
aggregates causes elevated ROS [44-46]. The mechanism by which this occurs remains
unclear, however, it may involve the disruption of ion gradients across cell membranes.
For example, pre-fibrillar amyloid aggregates share certain structural similarities with
other membrane pore-forming proteins and consequently the formation of unregulated
ion channels has been proposed as a possible mechanism for their cytotoxicity [47-49].
One suggestion is that ROS are elevated as a result of increased oxidative metabolism to
produce adenosine triphosphate (ATP) needed for pumping excess calcium out of the
cells [50]. Alternatively, it has been proposed that the A peptide interacts directly with
metal ions such as Cu2+ and Fe3+ (which are found at particularly high levels in amyloid
plaques [51]) to produce damaging H2O2 [52]. As previously mentioned, a likely
possibility for the generation of extracellular ROS in rheumatoid arthritis is stimulation of
neutrophils by aggregated IgG [36]. Similarly, the activation of microglia by amyloidforming A or prion peptides and the subsequent generation of ROS have been
implicated in neurodegenerative diseases [53-55]. The release of cytokines, such as IL-6
and IL-1, have also been linked to neuronal damage [54]. Moreover, minocycline (an
inhibitor of microglia activation) was found to be neuroprotective in a murine model of
Parkinson’s disease [56]. While autoantibodies against amyloid forming structures have
been found in Alzheimer’s patients [57] it is unclear whether classical autoimmunity
contributes to the pathology of this disease, although this has been suggested for other
PDDs including age-related macular degeneration [58] and renal disease [59].

Whether the causes of protein aggregate toxicity in individual diseases relate to physical
organ/tissue disruption resulting from the deposition of large insoluble aggregates, or to
the cytotoxic effects of smaller soluble oligomeric aggregates, to develop new therapies,
strategies will need to be adopted which target the relevant underlying molecular
mechanism(s). Regardless of the mode of toxicity, it appears likely that PDDs arise when
normally efficient protein folding quality control mechanisms are overwhelmed [60].
Therefore, increasing our understanding of extracellular protein folding quality control
will be very important in efforts to combat these diseases.

INTRACELLULAR PROTEIN FOLDING QUALITY CONTROL
Quality control of the correct transcription of RNA and translation of the polypeptide
sequence is extremely important for ensuring the adoption of correct native protein
conformation. The exonuclease activity of DNA polymerase and the proof-reading
activity of tRNA are the first lines of defence. However, mistakes in transcription or
translation are not always rectified and environmental conditions may promote the partial
unfolding of correctly folded proteins. Under these circumstances, the cells posttranslational quality control system may rescue abnormal proteins or target them for
destruction. Molecular chaperones are central to refolding pathways but also play an
important role in the targeting of non-native proteins to the proteasome or lysosomes for
degradation. Together these processes act to compensate for the relative instability of
proteins, generally preserving the current pool of proteins in their native conformations.
Extracellular proteins exit the cell after folding, maturation and modification in the

endoplasmic reticulum (ER). As it is an important site of protein synthesis and
trafficking, the ER possesses extensive protein folding quality control machinery. Once
polypeptides reach the ER, mistakes in folding or processing are recognized by an
intricate system of chaperones and resident proteases. If non-native proteins accumulate,
an unfolded protein response may be elicited which ultimately results in increased
expression of molecular chaperones and translocation proteins that either rescue and
refold the unfolded proteins or direct them to sites of intracellular proteolysis [61]. Nonnative proteins destined for secretion that evade the ER quality control may be recognized
as abnormal after reaching the golgi apparatus. This results in retrograde transport of the
protein back to the ER or re-targeting of the protein to a lysosome for degradation [62].
Together these actions ensure that only correctly folded proteins are secreted from normal
healthy cells. However, little is known regarding corresponding mechanisms that may
prevent the accumulation of unfolded proteins in extracellular spaces.

EXTRACELLULAR PROTEIN FOLDING QUALITY CONTROL
A 70 kg human contains around 5 L of blood and 10 L of other extracellular fluids
including interstitial fluid, cerebrospinal fluid and intraocular fluid. Whole plasma
contains around 7.5 % protein (by mass) [63]. This includes secreted proteins and
proteins that may have been shed from the cell surface or lost from damaged tissues.
Although a small number of proteins make a relatively large contribution to the
extracellular protein pool, it has been suggested that over 10,000 different proteins may
be normally present in plasma at low levels [64]. In the extracellular environment
proteins are exposed to various stresses that may induce partial unfolding; this includes

the hydraulic force of plasma being pumped around the body - hydrodynamic shear-stress
is known to contribute to protein unfolding [12, 65]. Additionally, the extracellular
environment is relatively more oxidising compared to the cytosol [66]. Increased plasma
protein oxidation (as determined by measuring protein carbonyl formation) is
characteristic of many disease states including Alzheimer’s disease [67], coronary artery
disease [68] and uremia [69]. Additionally, the most abundant blood protein, human
serum albumin, is known to be vulnerable to damage by ROS [69, 70].

To date, little is known about what (if any) specific mechanisms for protein folding
quality control operate in extracellular space. However, evidence has been gathered
suggesting that they are likely to exist. This includes the observation that unfolded
proteins are degraded more rapidly than native proteins in vivo [71]. Additionally,
polymorphonuclear leukocytes selectively catabolise denatured proteins compared to
native proteins [72] and lysosomal enzymes are implicated in this process [73].
Furthermore, liposomes with exposed surface hydrophobicity are cleared from circulation
more rapidly than those with a hydrophilic outer layer [74] and certain modifications of
human serum albumin, including oxidation and mutations that increase surface
hydrophobicity, enhance albumin clearance from circulating blood [75]. These findings
suggest that exposed hydrophobicity may target extracellular molecules for clearance
and/or degradation.

There is little evidence to support the existence of an extracellular proteolysis system
with specificity for unfolded proteins. While the concentration of plasma proteasome has

been measured at between 2.1-2.4 g/mL [76], this is 300 times less abundant than inside
cells [77]. Moreover, proteasomal degradation requires ATP which is around 1000 times
less abundant extracellularly [78]. Considering these limitations it is unlikely that a
system of this kind could participate significantly in extracellular protein folding quality
control. Intracellular chaperones may be released into extracellular fluids (e.g. after
necrotic cell death). While this may have some importance in vivo, it is probable that in
the instance of mass presentation of partially unfolded protein, such as might be
encountered during chronic inflammation, the chaperone capabilities of normally
intracellular chaperones (e.g. Hsp70 present in plasma at < 10 ng/mL [79]) would be
quickly overwhelmed. Furthermore, intracellular chaperones require ATP to effect
protein refolding which as previously mentioned is scarce in extracellular fluids.

A

MODEL

FOR

EXTRACELLULAR

PROTEIN

FOLDING

QUALITY

CONTROL
The discovery of three abundant extracellular proteins with chaperone activity is an
important landmark in understanding extracellular protein folding quality control. While
clusterin, haptoglobin and 2-macroglobulin do not appear to possess independent protein
refolding activity, their ability to stabilize stressed (partially unfolded) proteins is likely
to be important in preventing potentially pathological protein deposition [4-6, 80-82].
Several lines of evidence, reviewed in [26], support a role for ECs in the in vivo clearance
of aggregation-prone extracellular proteins:

1. ECs inhibit stress-induced protein aggregation in unfractionated human plasma, and
are found complexed with soluble amyloid-forming proteins in human extracellular
fluids.
2. Cell surface receptors are known for all three ECs, and all ECs have previously been
implicated in ligand transport across plasma membranes.
3. ECs are associated with extracellular protein deposits in numerous diseases, which
may be indicative of a failure in or the overwhelming of the machinery responsible for
quality control of extracellular protein folding.
The available evidence supports a model in which ECs bind to regions of exposed
hydrophobicity on extracellular stressed proteins to form soluble complexes which are
subsequently internalized via receptor-mediated endocytosis. Once internalized, the
complexes are most likely disposed of by proteolytic degradation within lysozomes. This
model is schematically represented in Figure 2. This mechanism is likely to have
profound effects on the development of many diseases for which pathology arises from
extracellular protein aggregation (see PROTEIN DEPOSITION DISEASES, above).

Figure 2. Proposed model of extracellular chaperone-assisted clearance of aberrantly folded proteins.
Extracellular chaperones (ECs) bind extracellular proteins in non-native (NN) conformations and facilitate
their uptake into cells via receptor-mediated endocytosis. Once internalised, the EC-NN complexes are
transported by vesicles towards the lysosome (L), where they are degraded. During this process, the
receptor is recycled back to the cell surface. Sites which may be of particular importance in this system are
the liver and macrophages.

POTENTIAL DRUG TARGETS
The discovery of components of a system for extracellular protein folding quality control
provides an opportunity to identify novel drug targets for those pathological mechanisms
that are out of reach of the intracellular protein folding quality control system.
Examining the pathways involved in extracellular protein quality control, a number of
possible targets are revealed. These include influencing protein aggregation with
chemical or peptidic chaperones, and increasing the expression of ECs and endocytic
receptors (Figure 3), discussed below.

Inhibition of Aggregate Formation and Toxicity by Chemical and Peptidic
Chaperones
Like their molecular chaperone counterparts, a wide range of naturally-occurring or
synthetic organic compounds have been reported to inhibit the aggregation/fibrillogenesis
of numerous PDD-causing proteins. In some instances, they have also exhibited the
potential to reduce aggregate-mediated cellular toxicity. Owing to their chaperone-like
properties, these small molecules have been termed “chemical chaperones” [83].
Chemical chaperones have been envisaged to modulate disease progression by reducing
aggregate formation leading in turn to decreased protein deposition, aggregate-mediated
cytotoxicity and inflammation. Inhibition of protein aggregation by chemical chaperones
may be achieved via one or more mechanisms: (i) steric hindrance of protein-protein
interaction, (ii) shielding regions of exposed hydophobicity or, (iii) in the case of amyloid
fibrillogenesis, minimizing structural changes leading to -sheet formation.

Figure 3. Potential therapeutic targets for inhibiting protein aggregate formation and related disease
progression. The available evidence suggests that quality control mechanisms exist in vivo to ensure that
partially unfolded extracellular proteins do not accumulate in tissues and organs (see Figure 2). Failure of
this system may lead to the onset of disease caused by one or both of the following: (i) the accumulation of
aberrantly folded assemblies such as insoluble amorphous aggregates, EC-associated deposits, or

degradation-resistant amyloid fibrils, or (ii) cytotoxic effects of pre-fibrillar species generated via the
amyloid assembly pathway. Potential targets for therapeutic interventions are (1) protein aggregation itself
(whether it leads to amorphous or amyloid deposits), which can be suppressed with small molecule
inhibitors, such as chemical chaperones and peptidic inhibitors, and overexpression of (2) extracellular
chaperones or (3) endocytic receptors. The latter two effects may enhance the uptake of EC-substrate
complexes, thereby increasing the rates of clearance and degradation of potentially pathogenic non-native
extracellular proteins.

Molecules such as Congo red and many benzofuran-based compounds have been shown
to reduce A-mediated cytotoxicity by preventing A fibrillogenesis or via direct
interactions with the soluble A oligomers [38, 84, 85]. In addition, Congo red
significantly reduced the cellular accumulation of amyloid-forming prion protein (PrP) in
scrapie-infected mouse cells [86]. Other small molecules such as nicotine can also
prevent fibrillogenesis of A by enhancing helix stability and preventing the -helix to sheet conversion required for A polymerization [87].

Osmolytes increase the thermodynamic stability of proteins by reducing the exposure of
their hydrophobic regions to solvent [88-90]. This promotes a hydrophobic collapse in
the unfolded protein leading to a rapid equilibrium shift towards a more stable
conformation. Exemplifying this, the osmolyte trimethylamine-N-oxide (TMAO) can
force highly unstructured proteins to fold into conformations that are native-like in
conformation [88]. Moreover, TMAO and other osmolytes including glycerol, dimethyl
sulfoxide (DMSO) and proline are reportedly able to assist the processing of diseaserelated mutant proteins [91, 92] and prevent their aggregation [93]. Despite showing

much promise, compared to protein chaperones, the lack of specificity and the high
(micromolar) concentrations required limit the use of chemical chaperones as effective
therapeutics in humans.

To overcome the limitations of chemical chaperones, several groups have investigated the
possible use of small peptides to inhibit protein aggregation and/or to reduce aggregatemediated cellular toxicity. The advantages of using peptidic inhibitors, as opposed to
non-peptidic compounds, include high efficacy and specificity. One approach utilises the
dual roles of ‘hybrid peptides’. These peptides typically contain a “recognition” domain,
for specific binding to target protein/s, and a “disrupting” domain, which interferes with
the protein aggregation event. In general, the recognition domain usually corresponds to
the

region(s)

of

the

target

protein

identified

as

being

critical

for

its

aggregation/fibrillogenesis. Once bound to the target protein, the disrupting domain
modulates protein aggregation via one of several mechanisms (e.g. steric hindrance,
charge repulsion, hydrophobicity) depending on the nature of the domain. The success of
this strategy has so far been demonstrated for A [94] and insulin [95].

Another approach for preventing aggregate formation focuses on the ability of some
peptides to interfere with -sheet formation and the stacking processes that is crucial for
amyloid fibril formation [96]. This strategy relies on three major properties of ‘-sheet
breaker’ peptides (i) to ensure specific binding -sheet breakers are usually derived from
the amyloidogenic sequences of their intended protein targets, (ii) known -sheetinterrupting amino acid residues, such as proline, are incorporated [97] and (iii) charged

residues are often added to either end of the peptide to improve solubility [98]. -sheet
breaker peptides have been shown to be effective in disrupting amyloid formation by A
[96, 99, 100], PrP [101], and the yeast prion protein Sup35 [102]. Although there is no
precedent for this in the literature, any small molecule approach directed towards
inhibiting extracellular protein aggregation and/or toxicity might conceivably also affect
receptor-mediated clearance processes. Thus, each potential therapeutic molecule would
need to be examined for such effects as part of characterizing it in vivo efficacy.

Inducing Expression of Extracellular Chaperones and Their Receptors
In vitro, at very low molar ratios of clusterin:substrate, clusterin enhances amyloid
formation, but has the opposite effect when present at higher but still sub-stoichiometric
ratios [103]. Moreover, complexes of clusterin and A formed at relatively high ratios of
clusterin:A (e.g. 1:10) were less toxic to neuroblastoma cells than A alone; in contrast,
complexes formed at low ratios of clusterin:A (e.g. 1:500) were more toxic than A
alone [103]. This suggests that increasing the levels of clusterin, and possibly other ECs,
would be protective in vivo. In fact, data from in vivo models suggest this is the case
(reviewed in [26]). Collectively, these data suggest that overexpression of ECs may prove
beneficial in PDDs such as Alzheimer’s disease. One potential route of therapy would be
to use small molecules to induce higher expression of ECs. Small molecules have been
found that can upregulate the heat shock response, subsequently increasing the
concentration of intracellular chaperones. One such molecule, arimoclomal, binds to heat
shock factor-1 (HSF-1) to prolong its activation [104] - this drug has been shown to
extend the lifespan of mice in a model of the PDD amyotrophic lateral sclerosis [105].

There has also been progress made through the use of high throughput screens of
hundreds of compounds to identify celastrol, a natural product from the Celastraceae
family of plants, as a heat shock inducer [106]. This may also be a useful approach in the
case of clusterin as it has an element in its promoter region that responds to HSF1 and
HSF2 [107]. Other pathways have also been indentified that control expression of these
ECs; the promoter regions of the clusterin, haptoglobin and 2-macroglobulin genes
contain AP-1 (activator protein-1) recognition motifs [108-110]. Thus the AP-1 pathway
provides additional targets for inducing EC expression.

However, increasing the expression of ECs may also have detrimental side effects.
Increased levels of clusterin are known to be associated with cancer progression and
clusterin is known to protect cells from chemotherapy drugs such as paclitaxel [111].
Moreover, increasing the levels of soluble chaperone-stressed protein complexes, without
increasing the throughput of pathways that would remove them, may increase toxicity. A
number of lines of evidence suggest that increasing the expression of receptors mediating
endocytosis of EC-stressed protein complexes may be a necessary adjunct to inducing EC
expression. For example, while 2-macroglobulin protected neuroblastoma cells
expressing LRP from A toxicity, it did not protect cells lacking LRP [112]. In this case
the protective effect of 2-macroglobulin could be inhibited by RAP (a pan-specific
inhibitor of LRP ligand binding). In addition, 2-macroglobulin has been shown to
promote A toxicity towards LRP-negative LAN5 cells but has the opposite effect with
LRP-expressing LAN5 transfectants [112]. Furthermore, in Alzheimer’s disease patients
there are increased plasma concentrations of several LRP ligands including ApoE, 1

anti-chymotrypsin and urokinase [113-115]; this raises the possibility that in Alzheimer's
disease LRP may be either overwhelmed or its expression downregulated. This has been
confirmed by data showing that LRP expression at the blood brain barrier is decreased in
Alzheimer’s disease patients and transgenic Aβ-overproducing mice [116].

It is important to note that a strategy of inducing the expression of receptors mediating
the uptake of EC-stressed protein complexes may be complicated by the fact that receptor
expression is controlled by signalling pathways also associated with the activation of
immune cells [117, 118]. Thus, using small molecule transcriptional activators to increase
the expression of the relevant cell surface receptors is likely to activate cells of the innate
immune system such as macrophages. Acute activation of cells such as microglia in the
Alzheimer’s brain [119] and Creutzfeldt-Jakob disease [120], and neutrophils in
rheumatoid arthritis [121] are thought to contribute to pathology by the release of toxic
mediators such as reactive oxygen species (ROS) and proinflammatory cytokines [122,
123].

Thus, the available evidence suggests that it may be quite difficult to identify and/or
design small molecules that increase the transcription of ECs and their receptors without
inducing unknown, possibly detrimental, side effects. Despite these complexities, ECs
remain an attractive target for potential therapeutics in PDDs, which are thought to arise
as a result of an age-dependent overloading or malfunction of the protein folding quality
control systems [124]. One potential way of controlling the expression of ECs and their
receptors, without affecting the expression of other genes, is by targeting their translation

rather than transcription. Recent work has shown that a small molecule designed to target
a site in ferritin mRNA can induce an increase in the rate of its translation [125]. Thus by
specifically targeting the mRNA of specific ECs and their receptors it may be possible to
eliminate the problem of the non-specific upregulation of a range of genes, controlled by
the promoter elements targeted. In order to reach the goal of using small molecules to
regulate elements of the extracellular protein folding quality control system, our
knowledge of this system needs to be increased. This expanded knowledge base will
become critically important as the population of the world continues to age resulting in
extracellular PDDs placing an ever increasing burden on society.

CONCLUDING REMARKS
Many serious human diseases, collectively known as the PDDs, have pathologies that
arise from the inappropriate aggregation and deposition of partially unfolded proteins. In
many cases, for example Alzheimer's disease and prion diseases, these processes occur
extracellularly. Although the mechanisms that act to control protein folding
intracellularly are relatively well understood, corresponding processes that operate
extracellularly have only recently begun to be identified. Abundant ECs and endocytic
cell surface receptors are likely to play important roles in clearing partially unfolded
extracellular proteins and preventing them causing pathologies. This new understanding
has broadened the potential therapeutic targets for PDDs to include, in addition to
chemical/peptidic chaperones, manipulation of the expression levels of ECs and
endocytic receptors.

References
1.

Dobson, C.M., Nature, 2003, 426, 884-90.

2.

Chiti, F.; Dobson, C.M., Annu. Rev. Biochem., 2006, 75, 333-66.

3.

Wickner, S.; Maurizi, M.R.; Gottesman, S., Science, 1999, 286, 1888-93.

4.

Humphreys, D.T.; Carver, J.A.; Easterbrook-Smith, S.B.; Wilson, M.R., J. Biol.
Chem., 1999, 274, 6875-6881.

5.

Yerbury, J.J.; Rybchyn, M.S.; Easterbrook-Smith, S.B.; Henriques, C.; Wilson,
M.R., Biochemistry, 2005, 44, 10914-25.

6.

French, K.; Yerbury, J.J.; Wilson, M.R., Biochemistry, 2008, 47, 1176-1185.

7.

Yerbury, J.J.; Stewart, E.M.; Wyatt, A.R.; Wilson, M.R., EMBO Rep., 2005, 6,
1131-6.

8.

Morimoto, R.I., Genes Dev., 2008, 22, 1427-38.

9.

Davies, K.J.A.; Delsignore, M.E., J. Biol. Chem., 1987, 262, 9908-9913.

10.

Stadtman, E.R.; Oliver, C.N., J. Biol. Chem., 1991, 266, 2005-2008.

11.

Zuo, L.; Christofi, F.L.; Wright, V.P.; Liu, C.Y.; Merola, A.J.; Berliner, L.J.;
Clanton, T.L., Am. J. Physiol. - Cell Physiol., 2000, 279, 1058-1066.

12.

Ker, Y.C.; Chen, R.H., Lebensmittel-Wissenschaft und-Technologie (Food Sci.
Techn.), 1998, 31, 107-113.

13.

Day, R.; Bennion, B.J.; Ham, S.; Daggett, V., J. Biol. Chem., 2002, 322, 189203.

14.

Radford, S.E., Trends Biochem. Sci., 2000, 25, 611-618.

15.

Kopito, R.R., Trends Cell Biol., 2000, 10, 524-531.

16.

Minton, A.P., Curr. Opin. Struct. Biol., 2000, 10, 34-40.

17.

Sipe, J.D., Crit. Rev. Clin. Lab. Sci., 1994, 31, 325-354.

18.

Dunker, A.K.; Lawson, C.J.; Brown, R.M.; Williams, R.M.; Romero, P.; Oh, J.S.;
Oldfield, C.J.; Campen, A.M.; Ratliff, C.M.; Hipps, K.W., J. Mol. Graph. Model.,
2001, 19, 26-59.

19.

Carrell, R.W., Trends Cell Biol., 2005, 15, 574-580.

20.

Carrell, R.W.; Gooptu, B., Curr. Opin. Struct. Biol., 1999, 9, 799-809.

21.

Carrell, R.W.; Lomas, D.A., The Lancet, 1997, 350, 134-135.

22.

Hamidi, A.L.; Liepnieks, J.J.; Uemichi, T.; Rebibou, J.M.; Justrabo, E.; Droz, D.;
Mousson, C.; Chalopin, J.M.; Benson, M.D.; Delpech, M.; Grateau, G., Blood,
1997, 90, 4799-4805.

23.

Kelly, J.W., Curr. Opin. Struct. Biol., 1996, 6, 11-17.

24.

Soto, C., FEBS Lett., 2001, 498, 204-207.

25.

Thomas, P.J.; Qu, B.; Pedersen, P.L., Trends Biochem. Sci., 1999, 20, 456-460.

26.

Wilson, M.R.; Yerbury, J.J.; Poon, S., Mol. Biosyst., 2008, 4, 42-52.

27.

Kosaka, K., Acta Neuropathol., 1978, 42, 127-134.

28.

Hof, P.R.; Bouras, C.; Perl, D.P.; Morrison, J.H., Acta Neuropathol., 1994, 87,
115-124.

29.

Murayama, S.; Mori, H.; Ihara, Y.; Tomonaga, M., Ann. Neurol., 1990, 24, 394405.

30.

Buxbaum, J.; Gallo, G., Hematol./Oncol. Clinics N. Am., 1999, 13, 1235-1248.

31.

Lin, J.; Markowitz, G.S.; Valeri, A.M.; Kambham, N.; Sherman, W.H.; Appel,
G.B.; D'Agati, V.D., J. Am. Soc. Nephrol., 2001, 12, 1482-1492.

32.

Korvatska, E.; Munier, F.L.; Chaubert, P.; Wang, M.X.; Mashima, Y.; Yamada,
M.; Uffer, S.; Zografos, L.; Schorderet, D.F., Invest. Opthamol. Vis. Sci., 1999,
40, 2213-2219.

33.

Lewis, H.B.; Straatsma, B.R.; Foos, R.Y., Opthamology, 1986, 93, 1098-1111.

34.

Crabb, J.W.; Miyagi, M.; Gu, X.; Shadrach, k.; West, K.A.; Sakaguchi, H.;
Kamei, M.; Hasan, A.; Yan, L.; Rayborn, M.E.; Salomon, R.G.; Hollyfield, J.G.,
Proc. Natl. Acad. Sci. USA, 2002, 99, 14682-14687.

35.

Jasin, H.E., J. Immunol., 1983, 130, 1918-1923.

36.

Lunec, J.; Blake, D.R.; McCleary, S.J.; Brailsford, S.; Bacon, P.A., J. Clin.
Invest., 1985, 76, 2084-2090.

37.

Janson, J.; Soeller, W.C.; Roche, P.C.; Nelson, R.T.; Torchia, A.J.; Kreutter,
D.K.; Butler, P.C., Proc. Natl. Acad. Sci. USA, 1996, 93, 7283-7288.

38.

Lorenzo, A.; Yanker, B.A., Proc. Natl. Acad. Sci. USA, 1994, 91, 12243-12247.

39.

Moechars, D.I.; Dewachter, I.; Lorent, K.; Reversé, D.; Baekelandt, V.; Naidu,
A.; Tesseur, I.; Spittaels, K.; Van Den Haute, C.; Checler, F.; Godaux, E.;
Cordell, B.; Van Leuven, F., J. Biol. Chem., 1999, 274, 6483-6492.

40.

Jason, J.; Soeller, W.C.; Roche, P.C.; Nelson, R.T.; Torchia, A.J.; Kreutter, D.K.;
Butler, P.C., Proc. Natl. Acad. Sci. USA, 1996, 93, 7283-7288.

41.

Bucciantini, M.; Glannoni, E.; Chiti, F.; Baroni, F.; Formigll, L.; Zurdo, J.;
Taddel, N.; Ramponi, G.; Dobson, C.M.; Stefani, M., Nature, 2002, 416, 507-510.

42.

Practico, D., Biochem. Pharmacol., 2002, 63, 563-567.

43.

Imamura, Y.; Noda, S.; Hashizume, K.; Shinoda, K.; Yamaguchi, M.; Uchiyama,
S.; Shimizu, T.; Mizushima, Y.; Shirasawa, T.; Tsubota, K., Proc. Natl. Acad. Sci.
USA, 2006, 103, 11292-11287.

44.

Bucciantini, M.; Calloni, G.; Chiti, F.; Formigli, L.; Nosi, D.; Dobson, C.M.;
Stefani, M., J. Biol. Chem., 2004, 279, 31374-31382.

45.

Davis, J.B., Neurodegeneration, 1996, 5, 441-444.

46.

Matsuoka, Y.; Picciano, M.; La Francois, J.; Duff, K., Neuroscience, 2001, 104,
609-613.

47.

Stefani, M.; Dobson, C.M., J. Mol. Med., 2003, 81, 678-699.

48.

Kourie, J.I.; Shorthouse, A.A., Am. J. Physiol. - Cell Physiol., 2000, 278, 10631087.

49.

Kourie, J.I.; Henry, C.L., Clin. Exp. Pharmacol. Physiol., 2002, 29, 741-753.

50.

Squier, T.C., Exp. Gerontol., 2001, 36, 1593-15500.

51.

Lovell, M.A.; Robertson, J.D.; Teasdale, W.J.; Campbell, J.L.; Markesbery, W.R.,
J. Neurol. Sci., 1998, 158, 47-52.

52.

Huang, W.; Atwood, C.S.; Hartshorn, M.A.; Multhaup, G.; Goldstein, L.E.;
Scarpa, R.C.; Cuajungco, M.P.; Gray, D.N.; Lim, J.; Moir, R.D.; Tanzi, R.E.;
Bush, A.I., Biochemistry, 1999, 38, 7609-7616.

53.

Garcao, P.; Oliveira, C.R.; Agostinho, P., J. Neurosci. Res., 2006, 84, 182-193.

54.

Marella, M.; Chabry, J., J. Neurosci., 2004, 24, 620-627.

55.

Veerhuis, R.; Boshuizen, R.S.; Familian, A., Curr. Drug Targets, 2005, 4, 235248.

56.

Wu, D.C.; Jackson-Lewis, V.; Vila, M.; Tieu, K.; Teismann, P.; Vadseth, C.;
Choi, D.K.; Ischiropoulos, H.; Przedborski, S., J. Neurosci., 2002, 22, 1763-1771.

57.

Gruden, M.A.; Davudova, T.B.; Malisauskas, M.; Zamotin, V.V.; Sewell, R.D.E.;
Voskresenskaya, N.I.; Kostanyan, I.A.; Sherstnev, V.V.; Morozova-Roche, L.A.,
Dement. Geriat. Cogn. Dis., 2004, 18, 165-171.

58.

Umeda, S.; Suzuki, M.T.; Okamoto, H.; Ono, F.; Mizota, A.; Terao, K.;
Yoshikawa, Y.; Tanaka, Y.; Iwata, T., FEBS J., 2005, 19, 1683-1685.

59.

Fasth, A.; Bengtsson, U.; Kaijser, B.; Wieslander, J., Kidney Int., 1981, 20, 500-4.

60.

Dobson, C.M., Trends Biochem. Sci., 1999, 24, 329-32.

61.

Brodsky, J.L.; Mc Cracken, A.A., Cell Dev. Biol., 1999, 10, 507-513.

62.

Arvan, P.; Rossmann, M.G.; Grau, U.M.; Zuber, H.; Frank, G.; Tratschin, J.D.,
Traffic, 2002, 3, 771-780.

63.

Georgiou, H.M.; Rice, G.E.; Baker, M.S., Proteomics, 2001, 1, 1503-1506.

64.

Wrotnowski, C., Genet. Eng. News, 1998, 2, 38-41.

65.

Schneider, S.W.; Nuschele, S.; Wixforth, A.; Gorzelanny, C.; Alexander-Katz, A.;
Netz, R.R.; Schneider, M.F., Proc. Natl. Acad. Sci. USA, 2007, 104, 7899-7903.

66.

Sitia, R.; Braakman, I., Nature, 2003, 426, 18-25.

67.

Conrad, C.C.; Marshall, P.L.; Talent, J.M.; Malakowsky, C.A.; Choi, J.; Gracy,
R.W., Biochem. Biophys. Res. Comm., 2000, 275, 678-681.

68.

Kaneda, H.; Taguchi, J.; Ogasawara, K.; Ohno, M., Atherosclerosis, 2002, 162,
221-225.

69.

Himmelfarb, J.; McMonagle, E., Kidney Int., 2001, 60, 358-363.

70.

Davies, K.J.A., J. Biol. Chem., 1987, 262, 9895-9901.

71.

Margineanu, I.; Ghetie, V., J. Theor. Biol., 1981, 90, 101-110.

72.

Bocci, V.; Masti, L.; Pacini, A.; Viti, A., Exp. Cell Res., 1968, 52, 129-139.

73.

Coffey, J.W.; de Duve, C., J. Biol. Chem., 1968, 243, 3355.

74.

Senior, J.; Delgado, C.; Fisher, D.; Tilcock, C.; Gregoriadis, G., Biochimica
Biophys. Acta, 1991, 1062, 77-82.

75.

Iwao, Y.; Anraku, M.; Yamasaki, K.; Kragh-Hansen, U.; Kawai, K.; Maruyama,
T.; Otagiri, M., Biochim. Biophys. Acta, 2006, 1764, 743-749.

76.

Lavabre-Bertrand, T.; Henry, L.; Carillo, S.; Guiraud, I.; Ouali, A.; Dutaud, D.;
Aubry, L.; Rossi, J.F.; Bureau, J.P., Cancer, 2001, 92, 2493-2500.

77.

Lightcap, E.S.; McCormack, T.A.; Pien, C.S.; Chau, V.; Adams, J.; Elliott, P.J.,
Clin. Chem., 2000, 46, 673-83.

78.

Farias, M., 3rd; Gorman, M.W.; Savage, M.V.; Feigl, E.O., Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H1586-90.

79.

Martin-Ventura, J.L.; Leclercq, A.; Blanco-Colio, L.M.; Egido, J.; Rossignol, P.;
Meilhac, O.; Michel, J.B., Atherosclerosis, 2007, 194, 334-41.

80.

Pavlicek, Z.; Ettrich, R., Coll. Czech. Chem. Comm., 1999, 64, 717-725.

81.

Poon, S.; Rybchyn, M.S.; Easterbrook-Smith, S.B.; Carver, J.A.; Pankhurst, G.J.;
Wilson, M.R., J. Biol. Chem., 2002, 277, 39532-39540.

82.

Wilson, M.R.; Easterbrook-Smith, S.B., Trends Biochem. Sci., 2000, 25, 95-8.

83.

Chaudhuri, T.K.; Paul, S., FEBS J., 2006, 273, 1331-49.

84.

Klunk, W.E.; Debnath, M.L.; Koros, A.M.; Pettegrew, J.W., Life Sci., 1998, 63,
1807-14.

85.

Howlett, D.R.; Perry, A.E.; Godfrey, F.; Swatton, J.E.; Jennings, K.H.;
Spitzfaden, C.; Wadsworth, H.; Wood, S.J.; Markwell, R.E., Biochem. J., 1999,
340 ( Pt 1), 283-9.

86.

Caughey, B.; Race, R.E., J. Neurochem., 1992, 59, 768-71.

87.

Salomon, A.R.; Marcinowski, K.J.; Friedland, R.P.; Zagorski, M.G.,
Biochemistry, 1996, 35, 13568-78.

88.

Baskakov, I.; Bolen, D.W., J. Biol. Chem., 1998, 273, 4831-4.

89.

Street, T.O.; Bolen, D.W.; Rose, G.D., Proc. Natl. Acad. Sci. USA, 2006, 103,
13997-4002.

90.

Auton, M.; Bolen, D.W., Proc. Natl. Acad. Sci. USA, 2005, 102, 15065-8.

91.

Brown, C.R.; Hong-Brown, L.Q.; Biwersi, J.; Verkman, A.S.; Welch, W.J., Cell
Stress Chaperones, 1996, 1, 117-25.

92.

Tamarappoo, B.K.; Verkman, A.S., J. Clin. Invest., 1998, 101, 2257-67.

93.

Yoshida, H.; Yoshizawa, T.; Shibasaki, F.; Shoji, S.; Kanazawa, I., Neurobiol.
Dis., 2002, 10, 88-99.

94.

Fulop, L.; Zarandi, M.; Datki, Z.; Soos, K.; Penke, B., Biochem. Biophys. Res.
Commun., 2004, 324, 64-9.

95.

Gibson, T.J.; Murphy, R.M., Protein Sci., 2006, 15, 1133-41.

96.

Soto, C.; Sigurdsson, E.M.; Morelli, L.; Kumar, R.A.; Castano, E.M.; Frangione,
B., Nat. Med., 1998, 4, 822-6.

97.

Wouters, M.A.; Curmi, P.M., Proteins, 1995, 22, 119-31.

98.

Adessi, C.; Soto, C., Curr. Med. Chem., 2002, 9, 963-78.

99.

Datki, Z.; Papp, R.; Zadori, D.; Soos, K.; Fulop, L.; Juhasz, A.; Laskay, G.;
Hetenyi, C.; Mihalik, E.; Zarandi, M.; Penke, B., Neurobiol. Dis., 2004, 17, 50715.

100.

Chen, Z.; Krause, G.; Reif, B., J. Mol. Biol., 2005, 354, 760-76.

101.

Permanne, B.; Adessi, C.; Fraga, S.; Frossard, M.J.; Saborio, G.P.; Soto, C., J
Neural. Transm. Suppl., 2002, 293-301.

102.

Zhang, Z.; Chen, H.; Bai, H.; Lai, L., Biophys. J., 2007, 93, 1484-92.

103.

Yerbury, J.J.; Poon, S.; Meehan, S.; Thompson, B.; Kumita, J.R.; Dobson, C.M.;
Wilson, M.R., FEBS Lett, 2007, 21, 2312-2322.

104.

Hargitai, J.; Lewis, H.; Boros, I.; Racz, T.; Fiser, A.; Kurucz, I.; Benjamin, I.;
Vigh, L.; Penzes, Z.; Csermely, P.; Latchman, D.S., Biochem. Biophys. Res.
Commun., 2003, 307, 689-95.

105.

Kieran, D.; Kalmar, B.; Dick, J.R.; Riddoch-Contreras, J.; Burnstock, G.;
Greensmith, L., Nat. Med., 2004, 10, 402-5.

106.

Westerheide, S.D.; Bosman, J.D.; Mbadugha, B.N.; Kawahara, T.L.; Matsumoto,
G.; Kim, S.; Gu, W.; Devlin, J.P.; Silverman, R.B.; Morimoto, R.I., J. Biol.
Chem., 2004, 279, 56053-60.

107.

Loison, F.; Debure, L.; Nizard, P.; Le Goff, P.; Michel, D.; Le Drean, Y.,
Biochem. J., 2006, 395, 223-231.

108.

Wong, P.; Taillefer, D.; Lakins, J.; Pineault, J.; Chader, G.; Tenniswood, M., Eur.
J. Biochem., 1994, 221, 917-925.

109.

Oliviero, S.; Cortese, R., EMBO J., 1989, 8, 1145-51.

110.

Schaefer, T.S.; Sanders, L.K.; Nathans, D., Proc. Natl. Acad. Sci. USA, 1995, 92,
9097-101.

111.

Park, D.C.; Yeo, S.G.; Wilson, M.R.; Yerbury, J.J.; Kwong, J.; Welch, W.R.;
Choi, Y.K.; Birrer, M.J.; Mok, S.C.; Wong, K.K., Neoplasia, 2008, 10, 964-72.

112.

Fabrizi, C.; Businaro, R.; Lauro, G.M.; Fumagalli, L., J. Neurochem., 2001, 78,
406-12.

113.

Aoyagi, T.; Wada, T.; Kojima, F.; Nagai, M.; Harada, S.; Takeuchi, T.; Isse, K.;
Ogura, M.; Hamamoto, M.; Tanaka, K.; et al., Experientia, 1992, 48, 656-9.

114.

Licastro, F.; Morini, M.C.; Polazzi, E.; Davis, L.J., J. Neuroimmunol., 1995, 57,
71-5.

115.

Taddei, K.; Clarnette, R.; Gandy, S.E.; Martins, R.N., Neurosci. Lett., 1997, 223,
29-32.

116.

Deane, R.; Wu, Z.; Sagare, A.; Davis, J.; Du Yan, S.; Hamm, K.; Xu, F.; Parisi,
M.; LaRue, B.; Hu, H.W.; Spijkers, P.; Guo, H.; Song, X.; Lenting, P.J.; Van
Nostrand, W.E.; Zlokovic, B.V., Neuron, 2004, 43, 333-44.

117.

Horvai, A.; Palinski, W.; Wu, H.; Moulton, K.S.; Kalla, K.; Glass, C.K., Proc.
Natl. Acad. Sci. USA, 1995, 92, 5391-5.

118.

Mietus-Snyder, M.; Glass, C.K.; Pitas, R.E., Arterioscler. Thromb. Vasc. Biol.,
1998, 18, 1440-9.

119.

Shie, F.S.; Woltjer, R.L., Curr. Med. Chem., 2007, 14, 2865-71.

120.

Van Everbroeck, B.; Dewulf, E.; Pals, P.; Lubke, U.; Martin, J.J.; Cras, P.,
Neurobiol. Aging, 2002, 23, 59-64.

121.

Ottonello, L.; Cutolo, M.; Frumento, G.; Arduino, N.; Bertolotto, M.; Mancini,
M.; Sottofattori, E.; Dallegri, F., Rheumatology, 2002, 41, 1249-60.

122.

Bal-Price, A.; Brown, G.C., J. Neurosci., 2001, 21, 6480-91.

123.

Henkel, J.S.; Beers, D.R.; Siklos, L.; Appel, S.H., Mol. Cell Neurosci., 2006, 31,
427-37.

124.

Muchowski, P.J.; Wacker, J.L., Nat. Rev. Neurosci., 2005, 6, 11-22.

125.

Tibodeau, J.D.; Fox, P.M.; Ropp, P.A.; Theil, E.C.; Thorp, H.H., Proc. Natl.
Acad. Sci. USA, 2006, 103, 253-7.

